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Distances to the nearest neighbors in the training sets
For each newly synthesized compound, we retrieved the 5 nearest neighbors (NN) in the training set for the BCRP model and for the P-gp model. For this, similarity was measured by Tanimoto on RDKit fingerprints to each and every compound of the two training sets. The 5 compounds with highest Tanimoto similarity are the 5 nearest neighbors. We then averaged the 5 similarities and looked at the structure and activity of the neighbors. The results are summarized in Table S1 and S2 below. 4.9 µM inactive 5 0.89 0 a % inhibition rates are given for these compounds at a concentration of 100µM compared to the positive control Ko143 (1µM), which was set as 100% inhibition rate. Data are given as mean from 3 independent experiments with duplicate measurements 0.9 µM inhibitor 5 0.90 5 a % inhibition rates are given for these compounds at a concentration of 100µM compared to the positive control verapamil (100µM), which was set as 100% inhibition rate. Data are given as mean from 3 independent experiments with triplicate measurements. Table 2 in (A) BCRP expressing PLB cells and (B) P-gp overexpressing CCRF-VCR1000 cells. IC50 measurements were accomplished as described in the materials and methods section. Data given here show the mean percentage fluorescence intensity after subtracting the background fluorescence of unstained cells and the fluorescence of the DMSO control and subsequent normalization to the positive control Ko143 for BCRP and verapamil for P-gp, which were set as 100%, ± SD of at least 3 independent experiments. Compound 11a was measured in 2 independent experiments for inhibition of BCRP. Non-linear regression analyses were performed as described in the materials and methods section. 
